Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD)
Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy treatment of MDD
PRAX-114 to advance in Phase 2b study in women with menopausal and mood symptoms
PRAX-944 Phase 2b study for treatment of essential tremor to initiate in 3Q21; Phase 2a topline results expected by the end of 2021
PRAX-562 Phase 1 healthy volunteer study completed with dose up to 150 mg and favorable safety profile
Cash and investments of $339.2 million as of June 30, 2021 supports runway into 2Q23
https://finance.yahoo.com/news/praxis-precision-medicines-provides-corporate-120000136.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.